Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner - PubMed (original) (raw)

Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner

P Podevin et al. Hepatology. 2001 Jun.

Abstract

The impact of hepatitis C virus NS5A protein mutations on interferon alfa (IFN-alpha) signaling pathway, cell proliferation, and viability is an important issue that is still under debate. We have therefore combined transient and stable expression in a human hepatocytic cell line (Huh7) of 3 full-length NS5A sequences, isolated from patients with or without response to IFN-alpha therapy. Expression of all 3 NS5A-reduced IFN-alpha global antiviral activity on both vesicular stomatitis virus (VSV) and encephalomyocarditis virus (EMCV) replication. We did not show, however, an effect of these 3 NS5A proteins on double-stranded RNA-dependent kinase (PKR) expression and activity as well as colocalization and coimmunoprecipitation between NS5A and PKR. We also failed to show an effect of the 3 NS5A mutants tested on cell proliferation and viability. Overall, our results support an important role of NS5A in controlling IFN-alpha antiviral activity; they show, however, that PKR-independent mechanisms are implicated, at least in liver-derived cells.

PubMed Disclaimer

Comment in

Hepatitis C virus and interferon resistance: it's more than just PKR.
Taylor DR. Taylor DR. Hepatology. 2001 Jun;33(6):1547-9. doi: 10.1053/jhep.2001.25447. Hepatology. 2001. PMID: 11391546 No abstract available.

Cited by

Enhanced apoptosis in post-liver transplant hepatitis C: effects of virus and immunosuppressants.
Lim EJ, Chin R, Angus PW, Torresi J. Lim EJ, et al. World J Gastroenterol. 2012 May 14;18(18):2172-9. doi: 10.3748/wjg.v18.i18.2172. World J Gastroenterol. 2012. PMID: 22611309 Free PMC article. Review.
Pathologic effects of RNase-L dysregulation in immunity and proliferative control.
Ezelle HJ, Hassel BA. Ezelle HJ, et al. Front Biosci (Schol Ed). 2012 Jan 1;4(2):767-86. doi: 10.2741/s298. Front Biosci (Schol Ed). 2012. PMID: 22202089 Free PMC article. Review.
Identification and characterization of a ross river virus variant that grows persistently in macrophages, shows altered disease kinetics in a mouse model, and exhibits resistance to type I interferon.
Lidbury BA, Rulli NE, Musso CM, Cossetto SB, Zaid A, Suhrbier A, Rothenfluh HS, Rolph MS, Mahalingam S. Lidbury BA, et al. J Virol. 2011 Jun;85(11):5651-63. doi: 10.1128/JVI.01189-10. Epub 2011 Mar 23. J Virol. 2011. PMID: 21430046 Free PMC article.
Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.
Yuan HJ, Jain M, Snow KK, Gale M Jr, Lee WM; HALT-C Trial Group. Yuan HJ, et al. J Viral Hepat. 2010 Mar;17(3):208-16. doi: 10.1111/j.1365-2893.2009.01169.x. Epub 2009 Jul 28. J Viral Hepat. 2010. PMID: 19656286 Free PMC article.
Ultra-structural localisation of hepatocellular PKR protein using immuno-gold labelling in chronic hepatitis C virus disease.
MacQuillan GC, Caterina P, de Boer B, Allan JE, Platten MA, Reed WD, Jeffrey GP. MacQuillan GC, et al. J Mol Histol. 2009 Jun;40(3):171-6. doi: 10.1007/s10735-009-9227-0. Epub 2009 Jul 30. J Mol Histol. 2009. PMID: 19642004

Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner - PubMed (original) (raw)